Related Experiment Video
Updated: Jul 5, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity
Tetsuo Tani1, Haritha Mathsyaraja2, Marco Campisi1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Inactivating TREX1 enzyme in cancer cells unleashes STING-IFN signaling, enhancing antitumor immunity. This approach sensitizes tumors to immune checkpoint blockade and cell therapies by boosting immunogenicity.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Oncology
Background:
- Cancers often evade immune detection by suppressing Stimulator of Interferon Genes (STING)-Interferon (IFN) signaling.
- Therapeutic strategies like STING agonists and epigenetic modifiers can restore antitumor immunity in preclinical cancer models.
Purpose of the Study:
- To investigate the role of three prime exonuclease 1 (TREX1) in regulating STING-IFN signaling within cancer cells.
- To explore the potential of targeting TREX1 to enhance cancer cell immunogenicity and therapeutic responses.
Main Methods:
- Assessed TREX1 expression and its correlation with STING-IFN signaling in cancer cells.
- Utilized TREX1 inactivation in preclinical mouse tumor models.
- Evaluated the impact of TREX1 targeting on immune cell recruitment, NK cell activity, and response to immune checkpoint blockade (ICB).
Main Results:
- Adaptive induction of TREX1 restrains STING-dependent nucleic acid sensing by degrading cytosolic DNA.
- TREX1 expression is upregulated by autocrine IFN and STAT1, preventing STING-IFN signal amplification.
- TREX1 inactivation in cancer cells activates STING-IFN signaling, recruiting T and NK cells, and enhancing sensitivity to IFNγ and ICB.
Conclusions:
- Targeting TREX1 can amplify cancer cell STING-IFN signaling, increasing tumor immunogenicity.
- TREX1 inactivation represents a complementary strategy to sensitize tumors to ICB and cell therapies.
- Modulating TREX1 offers a novel therapeutic avenue for overcoming immune evasion in cancer.
Related Concept Videos
Tumor Immunotherapy
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
The Tumor Microenvironment
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Intracellular Signaling Affects Focal Adhesions
Some...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

